All Stories

Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.

Mar 17, 2025 - 13:18
 0
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.
Read More

Tags:

Previous Article

Citygate diversifies with launch of new leasing business

Next Article

Q Energy to build 200MW solar PV in Spain

Related Posts

Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg

Gilead loses interest in Arcus' kidney cancer rival to ...

Feb 18, 2025  0

Sanofi bounces midstage ILT2 asset back to Biond Biologics after $125M bet

Sanofi bounces midstage ILT2 asset back to Biond Biolog...

Mar 3, 2025  0

J&J fails to ace Ventura, stopping phase 3 depression program over ‘insufficient efficacy’

J&J fails to ace Ventura, stopping phase 3 depression p...

Mar 7, 2025  0